Collaboration was a central theme of the recent BIO International Convention, which featured panel discussions on AMP-lifying Innovation: NIH, Patient Organizations & Leading Biopharma Firms Mobilize to Tackle Tough Diseases and Playing Nice in the Sandbox: Pre-Competitive Research Consortiums Offer Quicker, Less Expensive Path to Better Medicines.
Most Recent Posts
We all know that it only takes one storm to have severe impact, which is why we wanted to remind you that Rx Response stands ready to support any disaster that has wide-spread impact to pharmaceutical supply, and that all of our services are offered at no cost to government partners.
As the editorial from Patrick Kennedy and Husseini Manji in USA TODAY discusses why brain research is vital, some of the sentiments echo the discussion from our Mental Health Capitol Hill briefing last week.
PhRMA’s 2014 Medicines in Development for Parkinson’s Disease report highlighted the nearly 40 medicines in the pipeline that offer hope for the up to 1.5 million Americans affected by Parkinson’s disease (PD). Today we highlight Sue Dubman, one of those individuals living with PD and her inspirational story.
Biopharmaceutical research and development (R&D) is fueled by innovative minds with an eye toward the future. It has provided patients around the world with treatments to help them live healthier, more productive lives. This week, we focused on the ways in which innovation continues to help patients thrive and the unfortunate roadblocks that often hinder patient access to life-changing medicines.
The focus in recent weeks on the cost of a new cure for Hepatitis C has largely ignored the long-term value it provides to patients and the health care system broadly, including helping to prevent expensive hospitalizations and costly medical procedures, such as liver transplants.
It has become increasingly clear in recent weeks that far too many patients simply cannot access innovative medicines that help treat costly chronic diseases. While more Americans now have health care coverage under the Affordable Care Act (ACA), they still face insurmountable barriers to access that hinder our collective efforts to prevent, manage, and cure these conditions.
Innovation is the engine of economic growth and development. Research and development (R&D) spending is what creates jobs and makes innovation a reality. As the global economy continues to recover and regain its former strength, the pharmaceutical industry remains the world’s largest source of R&D spending. According to a recent article in the
“The biopharmaceutical industry’s top priority is to provide patients with access to innovative, life-saving medicines.”
For nearly 50 years the PhRMA Foundation has helped thousands of scientists advance their careers and has inspired new generations to enter biopharmaceutical research. The early-career support provided by the PhRMA Foundation has been a catalyst for scientists to become leaders in their organizations and fields. Their programs help build a larger pool of highly-trained researchers to meet the growing needs of academic institutions, the government and the research-intensive pharmaceutical industry. Are you one of them?
It’s no secret that when it comes to the Affordable Care Act, health insurance exchange coverage varies depending on where you live. From the plans offered, to premiums, to the type of Marketplace, not every state looks alike.
That’s why we created state-by-state fact sheets on health insurance exchange coverage and access to prescription medicines across the country.
In the guest blog below, Michele Lloyd-Puryear, Special Consultant to Genetic Alliance, discusses key findings from a patient-driven data collection effort intended to complement the Food and Drug Administration’s (FDA) patient-focused drug development initiative which was part of the most recent reauthorization of the Prescription Drug User Fee Act.